Longeveron granted U.S. patent for administration of MSCs

Longeveron (LGVN) announced that the United States Patent and Trademark Office, USPTO, has granted a patent covering administration of the Company’s proprietary Mesenchymal Stem Cells, MSCs, for the treatment of patients with symptoms of aging-related frailty. U.S. Patent No. 12,465,620, entitled “Method of Treating Aging Frailty in Subjects with Inflammaging Using Human Mesenchymal Stem Cells,” provides Longeveron with patent rights in the United States through 2038. Further patent term extension may occur along with regulatory exclusivity extensions.